Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
- Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
September 08, 2021
- Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer
August 23, 2021
- Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 11, 2021
- Xenon Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
August 10, 2021
Product Pipeline
XEN1101
for Epilepsy
X-TOLE Clinical Trial
XEN1101
for MDD
Collaboration with Mount Sinai
XEN496
for Epilepsy
EPIK Clinical Trial
XEN007
for Orphan Neurological Indications
Investigator-led study / Absence Epilepsy
NBI-921352
for Epilepsy
Partnered with Neurocrine Biosciences
FX301
for Post-Operative Pain
Partnered with Flexion Therapeutics
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
